Preclinical and first-in-human of purinostat mesylate, a novel selective HDAC I/IIb inhibitor, in relapsed/refractory multiple myeloma and lymphoma.
普利诺他甲磺酸盐（一种新型选择性 HDAC I/IIb 抑制剂）在复发/难治性多发性骨髓瘤和淋巴瘤中的临床前和首次人体试验
期刊:Signal Transduction and Targeted Therapy
影响因子:52.7
doi:10.1038/s41392-025-02285-w
Yang Linyu, Qiu Qiang, Wang Jie, Wen Yi, Li He, Liang Rui, Feng Yunyu, Wang Fang, Lin Xiaojing, Tang Minghai, Yang Jianhong, Pei Heying, Zhao Peng, Wang Jishi, Xiang Jin, Miao Jia, Zheng Li, Tan Ke, Wang Yongsheng, Hu Yiguo, Chen Lijuan, Zhao Weili, Niu Ting
